Jubilant Therapeutics Inc, a biopharmaceutical company, has collaborated with Boston Children's Hospital to assess peptidyl arginine deiminase 4 (PAD4) inhibitors under development by Jubilant Therapeutics, it was reported on Thursday.

The study is intended to explore the modulation of neutrophil extracellular traps (NETs)in preclinical models of neutrophil regulation and rheumatoid arthritis (RA). PAD4 is an enzyme that converts arginine to citrulline in histones and is highly expressed in neutrophils. Histone citrullination has been implicated in the formation of NETs which is believed to contribute to pro-inflammation and disease progression in many autoimmune disorders including RA, fibrosis, lupus and ARDS.

Syed Kazmi, president and CEO of Jubilant Therapeutics, said, 'We are pleased to announce our collaboration with Boston Children's Hospital, whose reputation as the nation's leading paediatric hospital and research enterprise make them an ideal partner as we endeavour to develop the next generation of therapeutics for autoimmune diseases. Dr Denisa Wagner, the lead investigator, has extensive experience both in the PAD4 space and the role of NETs in pathological inflammation, and we're thrilled to have her on the team.'